Catheter ablation for atrial fibrillation is an increasingly performed procedure which is indicated for patients with symptomatic paroxysmal or persistent atrial fibrillation. Even though recently published clinical trials have shown that uninterrupted oral anticoagulation in the peri-ablation period is associated with favourable clinical outcomes, practicing cardiologists are still reluctant to follow this recommendation and frequently stop, switch or bridge oral anticoagulants before the procedure. Our aim is to create a national registry of atrial fibrillation ablation procedures, the ALFA registry, to study how novel oral anticoagulants (NOACs) are managed in “real world” practice. Radiofrequency and cryoablation procedures will be included. We will investigate how this general management trend translates into short and long-term clinical outcomes and adverse events, also considering patients baseline characteristics. The ALFA registry will provide clinically useful information on how novel oral anticoagulants are managed in the peri-ablation period in order to extend and complement information derived from clinical trials.


We're not around right now. But you can send us an email and we'll get back to you, asap.


Log in with your credentials


Forgot your details?

Create Account